IPSC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Century Therapeutics Inc (IPSC) is not a good buy for a beginner investor with a long-term strategy at this time. The stock shows weak financial performance, insider and hedge fund selling, and lacks strong positive catalysts. Despite some technical indicators showing bullish trends, the overall sentiment and data do not support a strong buy decision.
The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 60.747, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock has a high chance of declining in the short term (-3.36% in the next week). Key support and resistance levels are Pivot: 2.332, R1: 2.557, S1: 2.106, R2: 2.696, S2: 1.967.
TD Cowen initiated coverage with a Buy rating, citing the potential of the company's lead asset CNTY-813 for type 1 diabetes. The MACD and moving averages indicate bullish trends.
Hedge funds and insiders are heavily selling the stock. Financial performance in Q4 2025 shows a 100% revenue drop and significant declines in net income and EPS. No recent news or congress trading data to support positive sentiment.
In Q4 2025, revenue dropped to $0 (-100% YoY), net income fell to -$19,171,000 (-46.85% YoY), and EPS decreased to -0.22 (-47.62% YoY). Gross margin remained at 100%, but the overall financial performance is weak.
TD Cowen initiated coverage with a Buy rating, citing intriguing preclinical data for the company's lead asset CNTY-813. The firm sees long-term shareholder value as the pipeline advances, but no price target was provided.
